Geriatric
Physical Therapy
Osteoporosis
What is Osteoporosis?
0Loss in total mineralized bone
0Disruption of normal balance of bone breakdown
and build up
0Osteoclasts: bone resorption, stimulated by PTH
0Calcitonin: inhibits osteoclastic bone resorption
0Major mechanisms:
0 Slow down of bone build up: osteoporosis seen in older
women and men (men after age 70)
0 Accelerated bone breakdown: postmenopausal
0 Normal loss .5% per year after peak in 20s
0 Up to 5% loss/year during first 5 years after menopause
Defining Osteoporosis
0 Osteoporosis as a disease characterized by low bone
mass and micro architectural deterioration of bone
tissue, leading to increased bone fragility and a
consequent increase in fracture risk. One in three
women and one in twelve men over 50 years of age
are affected. Early menopause (age <45)
Two components of the bone
0Cortical Bone
0 Dense and compact
0 Runs the length of the long bones, forming a hollow
cylinder
0Trabecular bone
0 Has a light, honeycomb structure
0 Trabeculae are arranged in the directions of tension
and compression
0 Occurs in the heads of the long bones
0 Also makes up most of the bone in the vertebrae
Bone cells
0Osteocytes - derived
from osteoprogenitor
cells
0Osteoblasts
0Osteoclasts
Mineralization of the bone
0 Calcification occurs by extracellular deposition of
hydroxyapatite crystals
0 Trapping of calcium and phosphate ions in
concentrations that would initiate deposition of calcium
phosphate in the solid phase, followed by its conversion
to crystalline hydroxyapatite
Hormonal Influence
0 Vitamin D
0 Parathyroid Hormone
0 Calcitonin
0 Estrogen
0 Androgen
Vitamin D
0Osteoblast have receptors for (1,25-(OH)2-D)
0Increases activity of both osteoblasts and
osteoclasts
0Increases osteocytic osteolysis (remodeling)
0Increases mineralization through increased
intestinal calcium absorption
0Feedback action of (1,25-(OH)2-D) represses
gene for PTH synthesis
Parathyroid Hormone
0 Accelerates removal of calcium from bone to increase
Ca levels in blood
0 PTH receptors present on both osteoblasts and
osteoclasts
0 Osteoblasts respond to PTH by
0 Change of shape and cytoskeletal arrangement
0 Inhibition of collagen synthesis
0 Stimulation of IL-6, macrophage colony-stimulating factor
secretion
Calcitonin
0 C cells of thyroid gland secrete calcitonin
0 Straight chain peptide - 32 aa
0 Synthesized from a large preprohormone
0 Rise in plasma calcium is major stimulus of calcitonin
secretion
0 Plasma concentration is 10-20 pg/ml and half life is 5 min
0 Osteoclasts are target cells for calcitonin
0 Major effect of calcitonin is rapid fall of plasma calcium
concentration caused by inhibition of bone resorption
0 Magnitude of decrease is proportional to the baseline rate
of bone turnover
Other systemic hormones
0 Estrogens
0 Increase bone remodeling
0 Androgens
0 Increase bone formation
0 Growth hormone
0 Increases bone remodeling
0 Glucocorticoids
0 Inhibit bone formation
0 Thyroid hormones
0 Increase bone resorption
0 Increase bone formation
WHO guidelines for determining
osteoporosis
0Normal: Not less than 1 SD below the avg. for
young adults
0Osteopenia: -1 to -2.5 SD below the mean
0Osteoporosis: More than 2.5 SD below the
young adult average
0Severe osteoporosis
0 More than 2.5 SD below with fractures
Osteoporosis
0 Mechanisms causing osteoporosis
0 Imbalance between rate of resorption and formation
0 Failure to complete 3 stages of remodeling
0 Types of osteoporosis
0 Type I
0 Type II
Osteoporosis - types
0 Postmenopausal osteoporosis (type I)
0 Caused by lack of estrogen
0 Causes PTH to overstimulate osteoclasts
0 Excessive loss of trabecular bone
0 Age-associated osteoporosis (type II)
0 Bone loss due to decreased bone turnover
0 Mal-absorption
0 Mineral and vitamin deficiency
When to Measure BMD in
Postmenopausal Women
0 All women 65 years and older
0 Postmenopausal women <65 years of age:
0 If result might influence decisions about
intervention
0 One or more risk factors
0 History of fracture
When Measurement of BMD Is
Not Appropriate
0 Healthy premenopausal women
0 Healthy children and adolescents
0 Women initiating ET/HT for menopausal
symptom relief (other osteoporosis therapies
should not be initiated without BMD
measurement)
Who Should Be Considered
for Prevention or Treatment?
0 Postmenopausal women with T-score below –2.0
with no risk factors
0 Postmenopausal women with T-score below –1.5
with one or more risk factors
Prevention of Bone Loss
Prevention of Bone Loss
0 Calcium
0 HRT
0 SERMS [Selective estrogen receptor modulators]
0 Calcitonin
0 Bisphosphonates
Who Gets Osteoporosis?
0 Age
0 Estrogen deficiency
0 Testosterone deficiency
0 Family history/genetics
0 Female sex
0 Low calcium/vitamin D intake
0 Poor exercise
0 Smoking
0 Alcohol
0 Low body weight/anorexia
0 Hyperthyroidism
Factors
0 Hyperparathyroidism
0 Prednisone use
0 Liver and renal disease (think about vit d synthesis)
0 Low sun exposure
0 Medications (antiepileptics, heparin)
0 Malignancies (metastatic disease; multiple myeloma can
present as osteopenia!)
0 Hemiplegia / immobility
0 Physical inactivity
0 Thin body type
0 Rheumatological conditions e.g. rheumatoid arthritis, ankylosing
spondylitis
0 High caffeine intake
Methods to evaluate for
osteoporosis
0Quantitative Ultrasonography
0Quantitative computed tomography
0Dual Energy X-ray Absorptiometry (DEXA)
0 ”gold standard”
0 Measurements vary by site
0 Heel and forearm: easy but less reliable (outcome of
interest is fracture of vertebra or hip!)
0 Hip site: best correlation with future risk hip fracture
0 Vertebral spine: predict vertebral fractures; risk of
falsely HIGH scores if underlying OA/osteophytes
Fracture Reduction
0 Goal: prevent fracture, not just treat BMD
0 Osteoporosis treatment options
0 Calcium and vitamin D
0 Calcitonin
0 Bisphosphonates
0 Estrogen replacement
0 Selective Estrogen Receptor Modulators
0 Parathyroid Hormone
Osteoporosis Treatment: Calcium and
Vitamin D
0Calcium and vit D supplementation shown to
decrease risk of hip fracture in older adults
01000 mg/day standard; 1500 mg/day in
postmenopausal women/osteoporosis
0Vitamin D (25 and 1,25): 400 IU day at least;
0 Frail older patients with limited sun exposure may
need up to 800 IU/day
Osteoporosis Treatment:
Calcitonin
0 Likely not as effective as bisphosphonates
0 200 IU nasally/day
0 Decrease pain with acute vertebral compression
fracture
Osteoporosis Treatment:
Bisphosphonates
0Decrease bone resorption
0Multiple studies demonstrate decrease in hip
and vertebral fractures
0Alendronate, risodronate
0Ibandronate (boniva): once/month
0Those at highest risk of fracture (pre-existing
vertebral fractures) had greatest benefit with
treatment
Bisphosphonate Associated Osteonecrosis
(BON)
0 Jaw osteonecrosis
0 Underlying significant dental disease
0 Usually associated with IV formulations
0 Case reports associated with oral formulations
Bisphosphonates: Contraindications
0 Renal failure
0 Esophageal erosions
Osteoporosis Treatment: Estrogen
Replacement
0 Reduction in bone resorption
0 Proven benefits in treatment
0 Increased cardiac risk, increased risk cancer
Osteoporosis Treatment: Selective
Estrogen Receptor Modulators
0 Raloxifene
0 Decrease bone resorption like estrogen
0 No increased risk cancer (decrease risk breast cancer)
0 Increase in vasomotor symptoms associated with
menopause
Reducing Fractures
0 1. Decrease osteoporosis/improve BMD
0 2. Decrease risk of break: hip protectors
0 3. Decrease risk of fall
Hip Protectors
0 Padding that fits under clothing
0 Multiple studies demonstrate effectiveness at
preventing hip fractures
0 Likely cost effective
Falls Reduction
0 Falls are a marker of frailty
0 Hip fracture is a marker of frailty
0 Mortality after hip fracture:?due to hip fracture or hip fracture
as marker for those who are declining?
0 Increased risk of falls:
0 Prior fall (fear of falling)
0 Cognitive decline
0 Loss of vision
0 Peripheral neuropathy
0 Weakness
0 Stroke
0 Medications: anticholinergics…
Current Guidelines
0 US Preventive Task Force
0 Test Bone Mineral Density in all women over age 65,
younger postmenopausal women with at least one risk
factor, and postmenopausal women with a history of
fracture
0 Treat patients with T score <-2 and no risk factors, T
score <1.5 if any risk factors, and anyone with prior
vertebral/hip fracture
Who is left out?
0 Older men
0 Not included in recommendations
0 Screening not recommended or paid for
0 Significant problem, risk of osteoporosis, risk of
fracture, especially after age 70, even more so after age
80
0 Significant evidence that men with osteoporosis benefit
from treatment
0 For the purpose of these guidelines a pragmatic decision
was made to separate the target client groups into 3 broad
categories:
0 1. Those with normal bone mass concerned with reducing
the risk together with people with mild bone changes
(osteopenia).
0 2. People with a clinical diagnosis of osteoporosis without
any history of fracture (#).
0 3. A frailer group with advanced bone changes usually
having sustained fractures (#).
Diet
Exercises
0 Prevent fracture
0 Aid bone density
Strength muscles , balance , coordination
0 High impact exercises jogging effect hip . Knee and spine
0 Weight lifting…..wrist
Exercises
0 According to the National Osteoporosis Foundation,
the best exercises for building and maintaining
bone density are:
0 Weight-bearing exercise, such as walking, that makes
you work against gravity while staying upright.
0 Muscle-strengthening exercise, such as weight lifting,
that makes you work against gravity in a standing,
sitting, or prone position.
THANXS

Lecture_09.pptx

  • 1.
  • 3.
  • 4.
    What is Osteoporosis? 0Lossin total mineralized bone 0Disruption of normal balance of bone breakdown and build up 0Osteoclasts: bone resorption, stimulated by PTH 0Calcitonin: inhibits osteoclastic bone resorption 0Major mechanisms: 0 Slow down of bone build up: osteoporosis seen in older women and men (men after age 70) 0 Accelerated bone breakdown: postmenopausal 0 Normal loss .5% per year after peak in 20s 0 Up to 5% loss/year during first 5 years after menopause
  • 5.
    Defining Osteoporosis 0 Osteoporosisas a disease characterized by low bone mass and micro architectural deterioration of bone tissue, leading to increased bone fragility and a consequent increase in fracture risk. One in three women and one in twelve men over 50 years of age are affected. Early menopause (age <45)
  • 6.
    Two components ofthe bone 0Cortical Bone 0 Dense and compact 0 Runs the length of the long bones, forming a hollow cylinder 0Trabecular bone 0 Has a light, honeycomb structure 0 Trabeculae are arranged in the directions of tension and compression 0 Occurs in the heads of the long bones 0 Also makes up most of the bone in the vertebrae
  • 8.
    Bone cells 0Osteocytes -derived from osteoprogenitor cells 0Osteoblasts 0Osteoclasts
  • 9.
    Mineralization of thebone 0 Calcification occurs by extracellular deposition of hydroxyapatite crystals 0 Trapping of calcium and phosphate ions in concentrations that would initiate deposition of calcium phosphate in the solid phase, followed by its conversion to crystalline hydroxyapatite
  • 10.
    Hormonal Influence 0 VitaminD 0 Parathyroid Hormone 0 Calcitonin 0 Estrogen 0 Androgen
  • 11.
    Vitamin D 0Osteoblast havereceptors for (1,25-(OH)2-D) 0Increases activity of both osteoblasts and osteoclasts 0Increases osteocytic osteolysis (remodeling) 0Increases mineralization through increased intestinal calcium absorption 0Feedback action of (1,25-(OH)2-D) represses gene for PTH synthesis
  • 12.
    Parathyroid Hormone 0 Acceleratesremoval of calcium from bone to increase Ca levels in blood 0 PTH receptors present on both osteoblasts and osteoclasts 0 Osteoblasts respond to PTH by 0 Change of shape and cytoskeletal arrangement 0 Inhibition of collagen synthesis 0 Stimulation of IL-6, macrophage colony-stimulating factor secretion
  • 13.
    Calcitonin 0 C cellsof thyroid gland secrete calcitonin 0 Straight chain peptide - 32 aa 0 Synthesized from a large preprohormone 0 Rise in plasma calcium is major stimulus of calcitonin secretion 0 Plasma concentration is 10-20 pg/ml and half life is 5 min 0 Osteoclasts are target cells for calcitonin 0 Major effect of calcitonin is rapid fall of plasma calcium concentration caused by inhibition of bone resorption 0 Magnitude of decrease is proportional to the baseline rate of bone turnover
  • 14.
    Other systemic hormones 0Estrogens 0 Increase bone remodeling 0 Androgens 0 Increase bone formation 0 Growth hormone 0 Increases bone remodeling 0 Glucocorticoids 0 Inhibit bone formation 0 Thyroid hormones 0 Increase bone resorption 0 Increase bone formation
  • 15.
    WHO guidelines fordetermining osteoporosis 0Normal: Not less than 1 SD below the avg. for young adults 0Osteopenia: -1 to -2.5 SD below the mean 0Osteoporosis: More than 2.5 SD below the young adult average 0Severe osteoporosis 0 More than 2.5 SD below with fractures
  • 16.
    Osteoporosis 0 Mechanisms causingosteoporosis 0 Imbalance between rate of resorption and formation 0 Failure to complete 3 stages of remodeling 0 Types of osteoporosis 0 Type I 0 Type II
  • 17.
    Osteoporosis - types 0Postmenopausal osteoporosis (type I) 0 Caused by lack of estrogen 0 Causes PTH to overstimulate osteoclasts 0 Excessive loss of trabecular bone 0 Age-associated osteoporosis (type II) 0 Bone loss due to decreased bone turnover 0 Mal-absorption 0 Mineral and vitamin deficiency
  • 18.
    When to MeasureBMD in Postmenopausal Women 0 All women 65 years and older 0 Postmenopausal women <65 years of age: 0 If result might influence decisions about intervention 0 One or more risk factors 0 History of fracture
  • 19.
    When Measurement ofBMD Is Not Appropriate 0 Healthy premenopausal women 0 Healthy children and adolescents 0 Women initiating ET/HT for menopausal symptom relief (other osteoporosis therapies should not be initiated without BMD measurement)
  • 20.
    Who Should BeConsidered for Prevention or Treatment? 0 Postmenopausal women with T-score below –2.0 with no risk factors 0 Postmenopausal women with T-score below –1.5 with one or more risk factors
  • 21.
    Prevention of BoneLoss Prevention of Bone Loss 0 Calcium 0 HRT 0 SERMS [Selective estrogen receptor modulators] 0 Calcitonin 0 Bisphosphonates
  • 22.
    Who Gets Osteoporosis? 0Age 0 Estrogen deficiency 0 Testosterone deficiency 0 Family history/genetics 0 Female sex 0 Low calcium/vitamin D intake 0 Poor exercise 0 Smoking 0 Alcohol 0 Low body weight/anorexia 0 Hyperthyroidism
  • 23.
    Factors 0 Hyperparathyroidism 0 Prednisoneuse 0 Liver and renal disease (think about vit d synthesis) 0 Low sun exposure 0 Medications (antiepileptics, heparin) 0 Malignancies (metastatic disease; multiple myeloma can present as osteopenia!) 0 Hemiplegia / immobility 0 Physical inactivity 0 Thin body type 0 Rheumatological conditions e.g. rheumatoid arthritis, ankylosing spondylitis 0 High caffeine intake
  • 24.
    Methods to evaluatefor osteoporosis 0Quantitative Ultrasonography 0Quantitative computed tomography 0Dual Energy X-ray Absorptiometry (DEXA) 0 ”gold standard” 0 Measurements vary by site 0 Heel and forearm: easy but less reliable (outcome of interest is fracture of vertebra or hip!) 0 Hip site: best correlation with future risk hip fracture 0 Vertebral spine: predict vertebral fractures; risk of falsely HIGH scores if underlying OA/osteophytes
  • 25.
    Fracture Reduction 0 Goal:prevent fracture, not just treat BMD 0 Osteoporosis treatment options 0 Calcium and vitamin D 0 Calcitonin 0 Bisphosphonates 0 Estrogen replacement 0 Selective Estrogen Receptor Modulators 0 Parathyroid Hormone
  • 26.
    Osteoporosis Treatment: Calciumand Vitamin D 0Calcium and vit D supplementation shown to decrease risk of hip fracture in older adults 01000 mg/day standard; 1500 mg/day in postmenopausal women/osteoporosis 0Vitamin D (25 and 1,25): 400 IU day at least; 0 Frail older patients with limited sun exposure may need up to 800 IU/day
  • 27.
    Osteoporosis Treatment: Calcitonin 0 Likelynot as effective as bisphosphonates 0 200 IU nasally/day 0 Decrease pain with acute vertebral compression fracture
  • 28.
    Osteoporosis Treatment: Bisphosphonates 0Decrease boneresorption 0Multiple studies demonstrate decrease in hip and vertebral fractures 0Alendronate, risodronate 0Ibandronate (boniva): once/month 0Those at highest risk of fracture (pre-existing vertebral fractures) had greatest benefit with treatment
  • 29.
    Bisphosphonate Associated Osteonecrosis (BON) 0Jaw osteonecrosis 0 Underlying significant dental disease 0 Usually associated with IV formulations 0 Case reports associated with oral formulations Bisphosphonates: Contraindications 0 Renal failure 0 Esophageal erosions
  • 30.
    Osteoporosis Treatment: Estrogen Replacement 0Reduction in bone resorption 0 Proven benefits in treatment 0 Increased cardiac risk, increased risk cancer
  • 31.
    Osteoporosis Treatment: Selective EstrogenReceptor Modulators 0 Raloxifene 0 Decrease bone resorption like estrogen 0 No increased risk cancer (decrease risk breast cancer) 0 Increase in vasomotor symptoms associated with menopause
  • 32.
    Reducing Fractures 0 1.Decrease osteoporosis/improve BMD 0 2. Decrease risk of break: hip protectors 0 3. Decrease risk of fall
  • 33.
    Hip Protectors 0 Paddingthat fits under clothing 0 Multiple studies demonstrate effectiveness at preventing hip fractures 0 Likely cost effective
  • 34.
    Falls Reduction 0 Fallsare a marker of frailty 0 Hip fracture is a marker of frailty 0 Mortality after hip fracture:?due to hip fracture or hip fracture as marker for those who are declining? 0 Increased risk of falls: 0 Prior fall (fear of falling) 0 Cognitive decline 0 Loss of vision 0 Peripheral neuropathy 0 Weakness 0 Stroke 0 Medications: anticholinergics…
  • 35.
    Current Guidelines 0 USPreventive Task Force 0 Test Bone Mineral Density in all women over age 65, younger postmenopausal women with at least one risk factor, and postmenopausal women with a history of fracture 0 Treat patients with T score <-2 and no risk factors, T score <1.5 if any risk factors, and anyone with prior vertebral/hip fracture
  • 36.
    Who is leftout? 0 Older men 0 Not included in recommendations 0 Screening not recommended or paid for 0 Significant problem, risk of osteoporosis, risk of fracture, especially after age 70, even more so after age 80 0 Significant evidence that men with osteoporosis benefit from treatment
  • 37.
    0 For thepurpose of these guidelines a pragmatic decision was made to separate the target client groups into 3 broad categories: 0 1. Those with normal bone mass concerned with reducing the risk together with people with mild bone changes (osteopenia). 0 2. People with a clinical diagnosis of osteoporosis without any history of fracture (#). 0 3. A frailer group with advanced bone changes usually having sustained fractures (#).
  • 38.
    Diet Exercises 0 Prevent fracture 0Aid bone density Strength muscles , balance , coordination 0 High impact exercises jogging effect hip . Knee and spine 0 Weight lifting…..wrist
  • 39.
    Exercises 0 According tothe National Osteoporosis Foundation, the best exercises for building and maintaining bone density are: 0 Weight-bearing exercise, such as walking, that makes you work against gravity while staying upright. 0 Muscle-strengthening exercise, such as weight lifting, that makes you work against gravity in a standing, sitting, or prone position.
  • 40.